Business · 25/10/20261 min read
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
Summary
The source item contains limited metadata.
Original source language: PR Newswire — Global News ReleasesOpen original release →